Evidence map›Paper›PMID 27008005›Full record

ArticleJournal of cancer research and clinical oncology2016

The predictive role of ADC values in prostate cancer patients treated with carbon-ion radiotherapy: initial clinical experience at Shanghai Proton and Heavy Ion Center (SPHIC).

Wei-Xiang Qi, Qing Zhang, Ping Li, Xiao-Meng Zhang, Guang-Yuan Zhang, Bin Wu, Jiade J Lu, Guo-Liang Jiang, Shen Fu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Combination ofCancer management and research · 2021
    Article
  4. Correlation of SUVMolecular imaging and radionuclide therapy · 2019
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wei-Xiang QiDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, No. 4365 Kang Xin Road, Shanghai, 201318, China.
Qing ZhangDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, No. 4365 Kang Xin Road, Shanghai, 201318, China.
Ping LiDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, No. 4365 Kang Xin Road, Shanghai, 201318, China.
Xiao-Meng ZhangDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, No. 4365 Kang Xin road, Shanghai, 201321, Shanghai, China.
Guang-Yuan ZhangDepartment of Radiology, Shanghai Proton and Heavy Ion Center, No. 4365 Kang Xin Road, Shanghai, 201318, China.
Bin WuDepartment of Radiology, Shanghai Proton and Heavy Ion Center, No. 4365 Kang Xin Road, Shanghai, 201318, China.
Jiade J LuDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, No. 4365 Kang Xin Road, Shanghai, 201318, China.
Guo-Liang JiangDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, No. 4365 Kang Xin Road, Shanghai, 201318, China.
Shen FuDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, No. 4365 Kang Xin road, Shanghai, 201321, Shanghai, China. fushen2014@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of our study was to investigate the predictive role of apparent diffusion coefficient (ADC) values in evaluating for therapeutic changes from carbon-ion radiotherapy (CIRT) in prostate cancer patients. MATERIALS AND

methodsThirty-one patients with prostate cancer treated with CIRT were enrolled in this retrospective study. Diffusion-weighted imaging (DWI) at 3-T was performed before and after CIRT. Before and after treatment, ADC values were measured in the tumors and in the benign tissues of the prostate, and serum prostate-specific antigen (PSA) levels were also assessed. We divided the patients into two groups: PSA response (PSA declines ≥50 %) and non-PSA response group (PSA declines <50 %).

resultsAfter CIRT treatment, the mean ADC value of the tumors (1.23 × 10(-3)mm(2)/s) was significantly increased as compared with the pretreatment value (1.07 × 10(-3)mm(2)/s) (p < 0.001), whereas the ADC values of the benign tissues after treatment did not significantly increase compared with the pretreatment values (p = 0.235). The mean PSA level was significantly reduced from 2.027 ng/mL before treatment to 0.822 ng/mL, respectively, after treatment (p = 0.0063). The mean of ADC changes in PSA response group before and after CIRT was significantly higher than that in non-PSA response group (∆ADC value: 0.217 vs 0.097 × 10(-3)mm(2)/s, p = 0.0229), and the rate of patients with PSA response was higher in the high ∆ADC group (∆ADC ≥ 0.10) than in the low ∆ADC group (∆ADC < 0.10) (72.7 and 33.3 %, respectively), but marginally significant (p = 0.056). Additionally, the baseline tumor ADC values revealed a negative correlation with changes in PSA levels after treatment (correlation coefficient, ρ = -0.524; p = 0.0025).

conclusionOur preliminary results suggest that ADC vales measurement may be a useful imaging biomarker for prediction and early assessment of therapeutic response of prostate cancer to CIRT.

Indexed as

AgedAged, 80 and overChinaHumansMagnetic Resonance ImagingMaleMiddle AgedProstatic NeoplasmsRadiotherapyRetrospective StudiesCarbon-ion radiotherapyDiffusion-weighted MRIProstate cancerProstate-specific antigen

Identifiers

PMID27008005
PMCPMC11819453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.